Ralf Gutzmer

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 27

Top Topics

Advanced Non Small Cell Lung Cancer

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Archives of dermatological research

Dermatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Viola K DeTemple, Antje Walter, Sabine Bredemeier, Ralf Gutzmer, Katrin Schaper-Gerhardt
Anti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization. Archives of dermatological research 316 (7) (2024)
Viola K DeTemple, Antje Walter, Sabine Bredemeier, Ralf Gutzmer, Katrin Schaper-Gerhardt
Anti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization. Archives of dermatological research 316 (7) (2024)
Viola K DeTemple, Antje Walter, Sabine Bredemeier, Ralf Gutzmer, Katrin Schaper-Gerhardt
Anti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization. Archives of dermatological research 316 (7) (2024)
Florentia Dimitriou, Phil Fang Cheng, Annalisa Saltari, Katrin Schaper-Gerhardt, Ramon Staeger, Veronika Haunerdinger, Federica Sella, Aizhan Tastanova, Christian Urban, Susanne Dettwiler, Daniela Mihic-Probst, Christian M Matter, Olivier Michielin, Ralf Gutzmer, Georgina V Long, Burkhard Becher, Mitchell Paul Levesque, Reinhard Dummer
A targetable type III immune response with increase of IL-17A expressing CD4 + T cells is associated with immunotherapy-induced toxicity in melanoma. Nature cancer (2024)
Paolo Antonio Ascierto, Reinhard Dummer, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion Sileni, Caroline Dutriaux, Jan Willem B de Groot, Naoya Yamazaki, Carmen Loquai, Caroline Robert, Keith T Flaherty
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF -Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Carola Berking, Elisabeth Livingstone, Dirk Debus, Carmen Loquai, Michael Weichenthal, Ulrike Leiter, Felix Kiecker, Peter Mohr, Thomas K Eigentler, Janina Remy, Katharina Schober, Markus Vincent Heppt, Imke von Wasielewski, Dirk Schadendorf, Ralf Gutzmer
COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma. Cancers 15 (18) (2023)
Åse Bratland, Eva Muñoz Couselo, Laurent Mortier, Osama Roshdy, Rene González, Jacob Schachter, Ana M Arance, Florent Grange, Nicolas Meyer, Abhishek Jagdish Joshi, Salem Billan, Brett G M Hughes, Jean-Jacques Grob, Karthik Ramakrishnan, Joy Ge, Burak Gumuscu, Ramona F Swaby, Ralf Gutzmer
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629. Dermatology and therapy (2023)
Reinhard Dummer, Philippa Corrie, Ralf Gutzmer, Tarek M Meniawy, Michele Del Vecchio, Celeste Lebbè, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stéphane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen Briscoe, James M G Larkin, Sandrine Mansard, Thierry Lesimple, Massimo Guidoboni, Silvia Sabatini, Erika Richtig, Rudolf Herbst, Maurice Lobo, Margarita Askelson, Paolo Antonio Ascierto, Michele Maio
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Jessica C Hassel, Lisa Zimmer, Thomas Sickmann, Thomas Kurt Eigentler, Friedegund Meier, Peter Mohr, Tobias Pukrop, Alexander Roesch, Dirk Vordermark, Christina Wendl, Ralf Gutzmer
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 15 (13) (2023)
Michèle Welti, Florentia Dimitriou, Ralf Gutzmer, Reinhard Dummer
Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAF V600 Melanoma: Current Status and Future Perspectives. Cancers 14 (22) (2022)
Ines Pires daSilva, Tasnia Ahmed, Jennifer Leigh McQuade, Caroline A Nebhan, John J Park, Judith M Versluis, Patricio Serra-Bellver, Yasir Khan, Tim Slattery, Honey K Oberoi, Selma Ugurel, Lauren E Haydu, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Patrick Terheyden, Michael Weichenthal, Ralf Gutzmer, Peter Mohr, Rajat Rai, Jessica L Smith, Richard A Scolyer, Ana M Arance, Lisa Pickering, James M G Larkin, Paul C Lorigan, Christian U Blank, Dirk Schadendorf, Michael A Davies, Matteo S Carlino, Douglas B Johnson, Georgina V Long, Serigne N Lô, Alexander M Menzies
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (10) (2022)
Maximilian Haist, Henner Stege, Berenice Mareen Lang, Aikaterini Tsochataridou, Martin Salzmann, Peter Mohr, Dirk Schadendorf, Selma Ugurel, Jan-Malte Placke, Michael Weichenthal, Ralf Gutzmer, Ulrike Leiter, Martin Kaatz, Sebastian Haferkamp, Carola Berking, Markus Vincent Heppt, Barbara Tschechne, Patrick Schummer, Christoffer Gebhardt, Stephan Grabbe, Carmen Loquai
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry. Cancers 14 (22) (2022)
Markus Vincent Heppt, Christoffer Gebhardt, Jessica C Hassel, Mareike Alter, Ralf Gutzmer, Ulrike Leiter, Carola Berking
Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives. Cancers 14 (19) (2022)
Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana M Arance, Jan Willem B de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandala, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Michelle Edwards, Paolo Antonio Ascierto
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, James M G Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen J Gogas, Stéphane Dalle, Nicolas Meyer, Paolo Antonio Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C Hassel, Caroline Robert, Matteo S Carlino, Anna Maria Di Giacomo, Marcus O Butler, Eva Muñoz Couselo, Michael P Brown, Piotr Lukasz Rutkowski, Andrew M Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz Merino, Andre van der Westhuizen, Alexander M Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J Tenney, Hao Tang, Georgina V Long
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Viola K DeTemple, Jessica C Hassel, Michael M Sachse, Imke Grimmelmann, Ulrike Leiter, Christoffer Gebhardt, Julia Eckardt, Claudia Pföhler, Yenny Angela, Hanna Hübbe, Ralf Gutzmer
Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients. Cancers 14 (21) (2022)
Jason A Chesney, Antoni Ribas, Georgina V Long, Joanne M Jeter, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F Gajewski, Ralf Gutzmer, Piotr Lukasz Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew M Haydon, John R Hyngstrom, Johannes V van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari M VanderWalde, Scott J Diede, James R Anderson, Sheryl Treichel, Edward L Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen J Gogas
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Peter Mohr, Emilie Scherrer, Chalid Assaf, Marc Bender, Carola Berking, Sheenu Chandwani, Thomas Kurt Eigentler, Imke Grimmelmann, Ralf Gutzmer, Sebastian Haferkamp, Jessica C Hassel, Axel Hauschild, Rudolf Herbst, Ruixuan Jiang, Katharina C Kähler, Clemens Krepler, Alexander Kreuter, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Claudia Pföhler, Anja Rudolph, Dirk Schadendorf, Maximo Schiavone, Gaston Schley, Patrick Terheyden, Selma Ugurel, Jens Ulrich, Jochen Sven Utikal, Carsten Weishaupt, Julia Welzel, Michael Weichenthal
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers 14 (7) (2022)
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James M G Larkin, Susana Puig Sardà, Paolo Antonio Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J M van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C Lorigan, Alexander C J van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert
Reply to E. Hindié. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (8) (2021)
Elias A T Koch, Anne Petzold, Anja Wessely, Edgar Dippel, Anja Gesierich, Ralf Gutzmer, Jessica C Hassel, Sebastian Haferkamp, Bettina Hohberger, Katharina C Kähler, Harald Knorr, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pföhler, Farnaz Rahimi, Dirk Schadendorf, Beatrice Schell, Max Schlaak, Patrick Terheyden, Kai-Martin Thoms, Beatrice Schuler-Thurner, Selma Ugurel, Jens Ulrich, Jochen Sven Utikal, Michael Weichenthal, Fabian Ziller, Carola Berking, Markus Vincent Heppt, null On Behalf Of The German Dermatologic Cooperative Oncology Group DeCOG Committee Ocular Melanoma
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Cancers 13 (13) (2021)
Ralf Gutzmer, Carmen Loquai, Caroline Robert, Brigitte Dréno, Alexander Guminski, Karl Lewis, Ramon Arntz, Serena Martelli, Nicholas Squittieri, Meenal Kheterpal
Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis. Dermatology and therapy 11 (5) (2021)
Susanne Mommert, Martin Jahn, Katrin Schaper-Gerhardt, Ralf Gutzmer, Thomas Werfel
Expression of histamine receptors H2R and H4R are predominantly regulated via the IL-4/IL-13 receptor type II on human M2 macrophages. Allergy 76 (9) (2021)
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James M G Larkin, Susana Puig, Paolo Antonio Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J M van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C Lorigan, Alexander C J van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (33) (2020)
Ralf Gutzmer, James A Solomon
Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma. Targeted oncology 14 (3) (2020)
Katrin Schaper-Gerhardt, Brigitta Köther, Luca Wolff, Aylin Kabatas, Manuela Gehring, Eirini Nikolouli, Susanne Mommert, Thomas Werfel, Ralf Gutzmer
The H4 R is highly expressed on eosinophils from AD patients and IL-4 upregulates expression and function via the JAK/STAT pathway. Allergy 76 (4) (2020)
Nora Möhn, Gernot Beutel, Ralf Gutzmer, Philipp Ivanyi, Imke Satzger, Thomas Skripuletz
Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook. Journal of clinical medicine 8 (11) (2019)
Lucie Heinzerling, Thomas K Eigentler, Michael Fluck, Jessica C Hassel, Daniela Heller-Schenck, Jan Leipe, Matthias Pauschinger, Arndt Vogel, Lisa Zimmer, Ralf Gutzmer
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO open 4 (3) (2019)